Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Appendicitis-II: Diagnostic Studies and Management01:29

Appendicitis-II: Diagnostic Studies and Management

Diagnosing and managing appendicitis requires a structured and comprehensive approach that spans from initial assessment to postoperative care. Here is an overview of the process:
Diagnosing Appendicitis
It requires a multifaceted approach, starting with a detailed physical examination to pinpoint the location and nature of the pain and identify any associated symptoms. Laboratory tests play a crucial role. A complete Blood Count (CBC) typically reveals leukocytosis (an increased number of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Nature communications·2026
Same author

Correction: The BrEasT cancer afTER-CARE (BETTER-CARE) programme to improve breast cancer follow-up: design and feasibility study results of a cluster-randomised complex intervention trial.

Trials·2026
Same author

Moving beyond anatomy: the future of rectal cancer management is biologically-informed, response-adapted, and patient-centered.

Clinical and translational radiation oncology·2026
Same author

Perioperative PD-1-inhibition in melanoma patients - a retrospective analysis from eight German skin cancer centers.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

Prognostic parameters for local control and survival after radiotherapy of stabilized bone metastases.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same author

Quantification of edge-enhancing effects using accelerated deep learning reconstructed orbital MRI sequences.

European journal of radiology open·2026

Related Experiment Video

Updated: Jun 22, 2026

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.3K

App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized

Lorenz Dörner1,2,3, Lucia Grosse1,2,3, Felix Stange1,2,3

  • 1Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.

Neuro-Oncology Practice
|May 13, 2024
PubMed
Summary

A smartphone app effectively collects patient-reported outcomes (PRO) for biomarker-guided cancer therapies. This pilot study shows high compliance and acceptance, paving the way for systematic PRO assessments in routine care.

Keywords:
biomarker-based therapyePROhealth-related quality of lifepersonalized medicine

More Related Videos

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Related Experiment Videos

Last Updated: Jun 22, 2026

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.3K
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Area of Science:

  • Oncology
  • Digital Health
  • Patient-Reported Outcomes

Background:

  • Biomarker-based therapies are increasingly common in cancer care outside clinical trials.
  • Systematic assessment of patient-reported outcomes (PRO) is crucial for incorporating patient perspectives.
  • The feasibility of electronic PRO assessment via smartphone was investigated.

Purpose of the Study:

  • To assess the feasibility and usability of a smartphone application for electronic patient-reported outcomes (ePRO) collection.
  • To evaluate patient and healthcare professional acceptance of the ePRO application.
  • To determine compliance rates with ePRO assessments in biomarker-guided cancer therapy.

Main Methods:

  • A smartphone application was developed by an interdisciplinary panel, incorporating validated HRQoL and symptom burden metrics.
  • Feasibility and usability were tested in a pilot study with 14 patients.
  • Qualitative content analysis of semi-structured interviews with patients and healthcare professionals (HCPs) was performed.

Main Results:

  • The app demonstrated feasibility and acceptance, with patients appreciating home-based, convenient data collection.
  • Compliance was high, with 82% of weekly distress thermometer questionnaires completed on time.
  • Median distress score was 5, and median Global health score was 58.3 (EORTC QLQ-C30).

Conclusions:

  • This pilot study confirms the feasibility and acceptance of the smartphone application for ePRO collection.
  • The findings support the expansion of the app for systematic PRO assessments in biomarker-guided therapies.
  • The study highlights the potential of digital health tools to enhance patient-centered cancer care.